Navigation Links
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
Date:9/17/2007

uctions in blood Phe levels in BH4-responsive patients. It also may enable some patients to minimize or eliminate highly-restrictive dietary constraints by increasing Phe tolerance levels. BioMarin and Merck Serono estimate that Kuvan could be a potential treatment option for approximately 30 percent to 50 percent of the estimated 50,000 identified PKU patients in the developed world.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). If approved, it will receive seven years of market exclusivity in the United States and 10 years in the European Union for this indication. Additionally, the FDA has granted Kuvan Fast Track designation, which is designed to facilitate the development of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). PAH is required for the metabolism of phenylalanine (Phe), an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. Currently, PKU can only be managed by a Phe-restricted diet, which is supplemented by nutritional replacement products, like formulas and specially-manufactured foods; however, the strict diet is difficult for most patients to adhere to the extent needed for ac
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NorthStar signs exclusive agreement with Illinois foundation
2. Can you keep ahead of progress? An exclusive interview with Rick Smith of iNoc
3. Is Rayovac IT Nirvana? An exclusive interview with Rick Dempsey, VP of IT
4. WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2
5. WTN exclusive interview with Tom Still, Wisconsin Technology Council
6. WTN exclusive interview with Commerce Secretary Cory Nettles (part 3)
7. WTN exclusive interview with Commerce Secretary Cory Nettles (part 2)
8. WTN exclusive interview with Commerce Secretary Cory Nettles (part 1)
9. Luem Software and Trek Bicycle sign exclusive software agreement
10. WTN Exclusive Interview: Cory L. Nettles, Secretary of Commerce
11. Epics Founder Judy Faulkner Speaks on Culture, Business Beliefs, and Recruiting: WTN Exclusive Coverage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Regis Technologies looks forward to ... Cancer Research (AACR) annual meeting. Regis will exhibit at ... Saturday, April 18, in Philadelphia and running through April ... of the oldest and largest organization focused on cancer ... and partners with survivors to promote awareness and research ...
(Date:4/16/2015)... , April 16, 2015  In recognition of World Hemophilia ... hemophilia advocacy groups to illuminate more than 15 prominent landmarks ... Boston,s Zakim Bridge and Prudential Tower, ... Orleans, Mercedes-Benz Superdome and Denver,s ... the evening of April 17, and coincide with hemophilia community ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... Avelas Biosciences, an in vivo ... today that it has initiated a Phase 1b study ... with primary, non-recurrent breast cancer undergoing surgery. In commencing ... of Steven Chen , M.D., as vice president ... escalation study will enroll up to 39 women with ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... 16, 2011  BioStorage Technologies, a global provider of comprehensive ... virtual sample intelligence and tracking for the bioscience industry, ... named "CFO of the Year" by the Indianapolis Business ... in the private companies category with $100 million or ...
... 15, 2011 Kevin W. Sharer, chairman and chief executive ... has announced his plan to retire from the Company at ... Amgen.  To facilitate an orderly transition process, Sharer will step ... chairman of the Company,s Board of Directors until December 31, ...
... WARREN, Mich., Dec. 15, 2011   Ecology Coatings, Inc. ... advanced coatings, today announced that it has developed bio-based ... Because these components are GRAS, they can be used ... and can be placed in direct contact with food ...
Cached Biology Technology:BioStorage Technologies' Mike Reffeitt Named "CFO of the Year" by Indianapolis Business Journal 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 3Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products 2
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
(Date:3/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces its biometric ... the products featured in 2015 "I Want That" International ... EST on the DIY Network.   DIY,s ... , site of the 2015 International CES for ...
(Date:3/18/2015)... 18, 2015 As mobile payments become ... smart wallets and apps continue to be introduced into the ... the mobile payment industry in focus today are:  NXT-ID, Inc. ... BABA ), Apple Inc. (NASDAQ: AAPL ... Inc. (NASDAQ: FB ) NXT-ID, Inc. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... in on finding an effective bait to get ahead ... is now killing not only lodgepole pine forests, but ... Research Chair in Forest Entomology in the University of ... emitted by the pest in North America,s lodgepole and ...
... multi-model-based assessment of so-called Durban Platform scenarios, conducted by ... Institute for Climate Impact Research (PIK) and the Fondazione ... is the current negotiation track at the Warsaw climate ... by 2015 to come into effect in 2020. ...
... new research shows that the Plasmodium vivax ... in 2010, may be "rapidly evolving" to overcome the natural ... Africans, scientists reported today at the annual meeting of the ... In large swaths of sub-Saharan Africa, some 95 ...
Cached Biology News:Bait research focused on outsmarting destructive beetle 2Success of climate talks vital for 2°C target 2Success of climate talks vital for 2°C target 3New research finds potential risk for millions in Africa believed resistant to vivax malaria 2New research finds potential risk for millions in Africa believed resistant to vivax malaria 3New research finds potential risk for millions in Africa believed resistant to vivax malaria 4
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... Hinge Region By immunoblotting the antibody reacts ... reacts with free MMP-2 or MMP-2 bound ... aqueous glycerol solution Solution in 0.01 ... 50% glycerol and 15 mM sodium azide. ...
Biology Products: